Impact of early initiation versus national standard of care of antiretroviral therapy in Swaziland’s public sector health system: study protocol for a stepped-wedge randomized trial

BackgroundThere is robust clinical evidence to support offering early access to antiretroviral treatment (ART) to all HIV-positive individuals, irrespective of disease stage, to both improve patient health outcomes and reduce HIV incidence. However, as the global treatment guidelines shift to meet this evidence, it is still largely unknown if early access to ART for all (also referred to as “treatment as prevention” or “universal test and treat”) is a feasible intervention in the resource-limited countries where this approach could have the biggest impact on the course of the HIV epidemics. The MaxART Early Access to ART for All (EAAA) implementation study was designed to determine the feasibility, acceptability, clinical outcomes, affordability, and scalability of offering early antiretroviral treatment to all HIV-positive individuals in Swaziland’s public sector health system.MethodsThis is a three-year stepped-wedge randomized design with open enrollment for all adults aged 18 years and older across 14 government-managed health facilities in Swaziland’s Hhohho Region. Primary endpoints are retention and viral suppression. Secondary endpoints include ART initiation, adherence, drug resistance, tuberculosis, HIV disease progression, patient satisfaction, and cost per patient per year.Sites are grouped to transition two at a time from the control (standard of care) to intervention (EAAA) stage at each four-month step. This design will result in approximately one half of the total observation time to accrue in the intervention arm and the other half in the control arm. Our estimated enrolment number, which is supported by conservative power calculations, is 4501 patients over the course of the 36-month study period.A multidisciplinary, mixed-methods approach will be adopted to supplement the randomized controlled trial and meet the study aims. Additional study components include implementation science, social science, economic evaluation, and predictive HIV incidence modeling.DiscussionA stepped-wedge randomized design is a causally strong and robust approach to determine if providing antiretroviral treatment for all HIV-positive individuals is a feasible intervention in a resource-limited, public sector health system. We expect our study results to contribute to health policy decisions related to the HIV response in Swaziland and other countries in sub-Saharan Africa.Trial registrationClinicalTrials.gov, NCT02909218. Registered on 10 July 2016.

[1]  Melbourne Victoria,et al.  A Ministry of Health , 1917, Nature.

[2]  J. Hughes,et al.  Design and analysis of stepped wedge cluster randomized trials. , 2007, Contemporary clinical trials.

[3]  G. Piaggio,et al.  Consort 2010 statement: extension to cluster randomised trials , 2012, BMJ : British Medical Journal.

[4]  Michael Rayment,et al.  Prevention of HIV-1 infection with early antiretroviral therapy , 2012, Journal of Family Planning and Reproductive Health Care.

[5]  J. Reinhard Report On The Global Hiv Aids Epidemic , 2016 .

[6]  T. Bärnighausen,et al.  Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial , 2013, Trials.

[7]  J. Robins,et al.  Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. , 2000, Epidemiology.

[8]  Deborah Watson-Jones,et al.  HPTN 071 (PopART): Rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment – a study protocol for a cluster randomised trial , 2014, Trials.

[9]  Wim Delva,et al.  Connecting the dots: network data and models in HIV epidemiology , 2016, AIDS.

[10]  R. Little,et al.  The prevention and treatment of missing data in clinical trials. , 2012, The New England journal of medicine.

[11]  R J Lilford,et al.  The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting , 2015, BMJ : British Medical Journal.

[12]  Deborah Donnell,et al.  Recent Patterns in Population-Based HIV Prevalence in Swaziland , 2013, PloS one.

[13]  G. Molenberghs Applied Longitudinal Analysis , 2005 .

[14]  H. Lane,et al.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.

[15]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[16]  S. Resch,et al.  Long-term financing needs for HIV control in sub-Saharan Africa in 2015–2050: a modelling study , 2016, BMJ Open.

[17]  J. Robins,et al.  Semiparametric regression estimation in the presence of dependent censoring , 1995 .

[18]  N. McGrath,et al.  Addressing social issues in a universal HIV test and treat intervention trial (ANRS 12249 TasP) in South Africa: methods for appraisal , 2015, BMC Public Health.

[19]  J. Larmarange The impact of universal test and treat on HIV incidence in a rural South African population : ANRS 12249 TasP trial, 2012-2016 , 2016 .

[20]  C. Krulewitch The global HIV/AIDS epidemic. , 2001, Journal of midwifery & women's health.